#USA #Frederick #Kemp Proteins #Avivo Biomedical #ECO Technology

Revolutionary Partnership for Universal Blood Technology

In a groundbreaking collaboration, Kemp Proteins has joined forces with Avivo Biomedical to reshape the future of emergency medicine, trauma response, and organ transplantation. This partnership focuses on the development and optimization of a revolutionary universal blood technology that promises to dissolve traditional barriers associated with blood type compatibility.

A New Era in Blood Supply

Imagine a world where blood type compatibility is no longer a hurdle in critical medical situations. This vision is what Avivo Biomedical is diligently working towards through its universal blood technology platform. With the help of Kemp Proteins, Avivo aims to transform type A, B, and AB blood into a universal donor type O, greatly expanding the availability and compatibility of blood for patients in urgent need.

How It Works

The innovative process involves a proprietary enzyme platform that safely cleaves the terminal sugars on blood cells responsible for each blood group. This enzymatic conversion results in Enzyme-Converted type O (ECO) blood and organs, eliminating the restrictive blood type barriers that currently limit organ and blood accessibility. Medical professionals envision this technology having significant impact not just in civilian healthcare but also in military and disaster response settings, where the demand for compatible blood is critical.

To ensure successful implementation, Kemp Proteins will be concentrating on the optimization of both upstream and downstream processes. Their expertise in recombinant protein expression, purification strategies, and bioprocessing will play a pivotal role in improving the scalability and manufacturability of Avivo's groundbreaking enzyme technologies.

Accelerating the Timeline

John Coleman from Avivo Biomedical expressed his enthusiasm about the collaboration, stating, "Kemp Proteins' expertise in scalable bioprocessing is vital for accelerating our timeline in getting universal blood technology to critical care settings." The partnership is aligned with the NATO Defence Innovation Accelerator for the North Atlantic (DIANA) 2026 program, reinforcing the strategic importance of next-generation transfusion technologies.

A Promising Future

With the recognition received from NATO, both Kemp and Avivo are stepping forward into a promising future. This partnership is essential in tackling some of the most pressing challenges related to blood and organ compatibility, paving the way for better healthcare solutions globally.

Kemp Proteins CEO, Mike Keefe, remarked, "We are proud to be part of these efforts and commend Avivo on their achievement. We look forward to supporting the next phase of their development." Avivo Biomedical’s unique approach aims not only to solve existing medical concerns but also addresses broader defense and security needs through innovative healthcare solutions.

About Kemp Proteins

Founded in Frederick, MD, Kemp Proteins specializes in biomanufacturing, focusing on recombinant protein production, protein engineering, and cell line development. Their commitment to advanced technologies positions them at the forefront of innovations that serve multiple sectors, from therapy to diagnostics and next-gen biologics.

About Avivo Biomedical

Based on a mission to enhance organ transplant rates and blood supply, Avivo harnesses powerful enzymes to eliminate the blood type barrier. Their pioneering work signifies a transformative leap in both military trauma response and the organ donation framework. With recent proof-of-concept studies showing promise in organ transplantation, they are gearing up for human clinical trials, potentially changing the landscape of medical care as we know it.

By enabling this ambitious endeavor, both Kemp Proteins and Avivo Biomedical showcase the incredible potential of collaborative innovation in healthcare, pushing boundaries to deliver more efficient and inclusive medical solutions to the public.